newsfilter
← Latest News
PR Newswire·

AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Realigning cost structure from a focus on commercialization to a focus on development to advance late-stage pipeline; expected to result in annual savings of $9 million Completed acquisition of Lowell Therapeutics and nafamostat franchise, including Ni